

NIA Internal Use Only

Applicant's last name, first initial	Abbreviated title	Submission date (mm/dd/yyyy)

CAENORHABDITIS INTERVENTIONS TESTING PROGRAM (CITP)

NOMINATION FORM

Deadline for submission, June 1st, 2026

Instructions

This application form is to nominate compounds (e.g., single molecule, combination of molecules) for consideration as pharmacological interventions by the [CITP](#). Individuals who wish to propose more than a single compound must use separate application forms for each proposed intervention. Applications are evaluated based on scientific merit, the potential of the proposed compound to extend lifespan and/or delay the onset of disease/disfunction, cost reasonableness and logistical constraints.

Proprietary compound(s) for which the chemical structure/composition cannot be disclosed for publication are not accepted.

Applications must be submitted as a single file to Dr. Tiziana Cogliati (NIAITP_CITP@mail.nih.gov) by the end of the day (US Pacific Time) on May 31st, 2026. Refer to the [CITP Intervention Nomination Guide](#) for additional information.

Resubmissions should follow the same instructions herein. In addition, they must include responses to the comments from the prior scientific review and explain how the application has been modified and strengthened. New data from any work completed since the original application was submitted should be described in the main body of the application, if deemed essential to support the concept.

When gathering information to include in this nomination, please consider any of the following, if available:

- Data from studies of lifespan in rodents or invertebrates
- Data from studies in human or model organisms on the compound's effects on diseases and processes thought to play a role in aging
- Data from cell culture experiments showing an effect on the hallmarks of aging
- Epidemiological evidence of health benefits
- Data on stability in solution
- Data on bioavailability, efficacy and toxicity in *Caenorhabditis* or other model organisms

NIA Internal Use Only

Applicant's last name, first initial

Abbreviated title

Submission date
(mm/dd/yyyy)**CAENORHABDITIS INTERVENTIONS TESTING PROGRAM (CITP)
NOMINATION FORM****Cover Page**

Name of Intervention	<i>Typically, the name of the compound (molecule, combination of molecules) to be tested</i>
Applicant Name, Degree(s):	
Institution:	
Address:	
Phone:	
Email:	
Co-Applicant Name, Degree(s):	
Institution:	
Address:	
Phone:	
Email:	
Submission Type	☐ Original or ☐ Re-submission <i>{previous submission date} (mm/dd/yyyy)</i>

NIA Internal Use Only

Applicant's last name, first initial

Abbreviated title

Submission date
(mm/dd/yyyy)

Nomination Justification

There is no page limit, but we encourage all applicants to be concise and recommend containing the Nomination Justification section within a maximum of three pages (including figures and tables). Please, compile the Nomination Justification following the four headings below.

1. Background and Rationale

*Describe concisely the reason why the proposed intervention deserves to be evaluated in *Caenorhabditis* for potential effects on lifespan and aging phenotypes.*

The following questions should be addressed:

- *What is the conceptual basis in support of testing this compound in *Caenorhabditis*?*
- *What is known about the chemistry of the compound to be tested? -Note that the compound identity must be disclosed to the CITP team.*
- *What is known about the compound safety profile?*
- *What effects on lifespan, disease(s) of aging, hallmarks of aging, or pathways involved in aging are known?*

This section should include the following if available:

- *Preliminary data showing the ability of the compound to either a) extend lifespan in worm/other model organisms, b) prevent disease in humans/other model organisms, c) target one or more of the hallmarks of aging, d) modulate a biological pathway involved in aging, or e) any other data in support of testing the proposed compound.*
- *If data are unpublished, include enough information to permit its evaluation.*

2. Suggested Treatment Information

Provide a detailed description of and rationale for the proposed treatment. The following questions should be addressed:

- *Is the compound soluble in water? If not, what solvent should be used and what should be the final dilution of the solvent? What are the recommended storage conditions for the stock and working solutions?*
- *How stable is the compound in solution at room temperature (CITP testing is performed at or above 20°C)? Is it sensitive to light or heat?*
- *Is the median effective dose (ED50) in human or in animal models known?*
- *What dose(s) are recommended for testing?*
- *Is there an assay to monitor the predicted effect of the intervention in *Caenorhabditis*? If the test requires specialized expertise or equipment, is this available in the compound nominator's laboratory?*

NIA Internal Use Only

Applicant's last name, first initial

Abbreviated title

Submission date
(mm/dd/yyyy)

3. Toxicity

*Describe what is known about potential harmful effects of the treatment in *Caenorhabditis*, including toxicity data obtained with doses of the compound other than the one(s) proposed for testing, or obtained when testing similar compounds. Note that if during the pilot/early phases of the CITP pipeline toxicity is observed in *Caenorhabditis* on plates at all concentrations tested, the testing will be terminated.*

- *If pilot toxicity data is available, describe the experimental conditions and any harmful side effects noted.*
- *Include information on the modality under which the side effect was observed (e.g., immediate or delayed), whether a dose reduction or more frequent dosing ameliorated the side effect (e.g., by preventing the accumulation of toxic metabolites).*
- *Are the median toxic dose (TD50) and/or median lethal dose (LD50) in human or in animal models known?*

4. Costs

The CITP covers all costs for testing and statistical analysis. It also includes a limited budget for purchase or cost-shared purchase of test compounds. The following should be addressed in this section:

- *What is the recommended source of the compound to be tested? If available commercially, which supplier(s) are suggested and why?*
- *If the compound can be purchased from commercial sources, provide an estimate of the cost of obtaining a sufficient supply to complete the test at all three CITP testing sites. Consider that the CITP will need to prepare a volume of approximately 350 ml of stock solution over the course of the study.*
- *If the compound is not available commercially and cannot be provided to the CITP without charge, provide a cost estimate for a sufficient supply of the compound to test, and indicate if you can cover the cost in full or in part.*

NIA Internal Use Only

Applicant's last name, first initial

Abbreviated title

Submission date
(mm/dd/yyyy)

References

Insert a list of references here

NIA Internal Use Only

Applicant's last name, first initial

Abbreviated title

Submission date
(mm/dd/yyyy)

Applicant (and co-Applicant) Biosketch or CV

Insert biosketch(es) or CV(s) of all applicants/co-applicants here.

NIA Internal Use Only

Applicant's last name, first initial

Abbreviated title

Submission date
(mm/dd/yyyy)

Statement of Understanding

Check all the boxes and sign at the end of the Statement of Understanding

In submitting this proposal, I agree to the following:

- I understand all information presented in the proposal can be freely shared with members of the CITP Steering Committee and Access Panel during their evaluation of proposals but will otherwise be considered confidential. ☐
- I understand that the molecular structure and/or composition of the tested compound(s) as well as the data generated by CITP-supported experiments using the compound(s) proposed will be made publicly available and can be used in applications for further research supported by anyone. I also will be free to use CITP-generated data in the context of applications for research funding support or for dissemination purposes. ☐
- I understand that, if the compound(s) proposed makes use of materials that are not yet freely available and whose production depends on unpublished methods, upon approval for entering the CITP pipeline, a mutually acceptable Materials Transfer Agreement (MTA) will be executed between my institution/organization and the institutions involved in the CITP. The content of the MTA will be provided by the NIA and will cover the transfer to the CITP and the conditions of use of the compound(s) needed for the experimentation. ☐

Name of Nominator

Signature of Nominator

Date (mm/dd/yyyy)